Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

@article{Fennelly1997PhaseIA,
  title={Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.},
  author={David William Fennelly and Carol A. Aghajanian and Fred Shapiro and C O'flaherty and Michael S McKenzie and Chris O'Connor and William Tong and Larry Norton and David R. Spriggs},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 1},
  pages={187-92}
}
PURPOSE Paclitaxel has shown significant activity in advanced ovarian cancer. In vitro studies with paclitaxel have suggested that fractionated brief infusion schedules may be more effective than the standard 24-hour infusion. We commenced a phase I evaluation of escalating-dose paclitaxel (40, 50, 60, 80, 100 mg/m2) administered weekly as a 1-hour infusion in patients with recurrent ovarian cancer. All patients had received prior paclitaxel and cisplatin therapy. All patients received standard… CONTINUE READING